[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

Glaukos Corporation (GKOS)

Glaukos Corporation (GKOS) stock sees mixed sentiment despite FDA approval and strong Q3 earnings. Analysts are raising price targets, but market caution and recent price drops are influencing investor sentiment.

About Glaukos Corporation

Glaukos Corporation is a healthcare company specializing in ophthalmic medical devices and therapies.
Glaukos Corporation uses the ticker $GKOS for trading. Listed in the Stocks category within the Healthcare sectors.

Insights

Glaukos Corporation (GKOS) market dominance near a 52-week low at XXXXXXX.
Glaukos Corporation (GKOS) trading volume is up XXXXX% from the previous week.
Glaukos Corporation (GKOS) social dominance is up XXX% from the previous week.
Glaukos Corporation (GKOS) creators is up XXXXX% from the previous week.
Glaukos Corporation (GKOS) mentions is up XXXXX% from the previous week.

Price: $XXXXXX

Price 24-Hour Time-Series Raw Data
The stock is trading lower due to broader market caution and recent price drops, which are overshadowing positive catalysts like FDA approval and strong Q3 earnings, despite analyst upgrades suggesting potential upside.

24-Hour: XXXX% 7-Day: XXXX% 30-Day: XXXXX%

1-Year High: $XXXXXX on 2025-01-23
1-Year Low: $XXXXX on 2025-10-24

AltRank: XXXXX

AltRank Line Chart
AltRank 24-Hour Time-Series Raw Data
Glaukos Corporation (GKOS) is currently AltRank #1,342 based on combined combined social and market metrics Daily Average: XXXXX
X Week: XXXXX -XX
X Month: XXXXX +216
X Months: XXXXX +773
X Year: XXXXX +970
1-Year High: XXXXX on 2025-09-13
1-Year Low: XX on 2024-12-29

Galaxy Score: XXXXX

Galaxy Score Line Chart
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XX
X Week: XX -XX
X Month: XX -XX
X Months: XX +4
X Year: XX +5
1-Year High: XX on 2025-03-03
1-Year Low: XX on 2025-07-17

Engagements: XXX (24h)

Engagements Line Chart
Engagements 24-Hour Time-Series Raw Data
Current Value: XXX
Daily Average: XXXXX
X Week: XXXXX -XX%
X Month: XXXXXXX -XX%
X Months: XXXXXXX +50%
X Year: XXXXXXX -XX%
1-Year High: XXXXXX on 2025-10-30
1-Year Low: XX on 2025-01-30

Engagements by network (24h): X: XXX YouTube: XX

Mentions: XX (24h)

Mentions Line Chart
Mentions 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XX
X Week: XX +23%
X Month: XXX -XX%
X Months: XXXXX +74%
X Year: XXXXX +31%
1-Year High: XXX on 2025-06-30
1-Year Low: X on 2025-09-01

Mentions by network (24h): X: XX YouTube: X

Creators: XX (24h)

Creators Line Chart
Creators 24-Hour Time-Series Raw Data
XX unique social accounts have posts mentioning Glaukos Corporation (GKOS) in the last XX hours which is down XX% from XX in the previous XX hours Daily Average: XX
X Week: XX +12%
X Month: XXX -XX%
X Months: XXXXX +203%
X Year: XXXXX +127%
1-Year High: XXX on 2025-06-30
1-Year Low: X on 2025-09-01

The most influential creators that mention Glaukos Corporation in the last XX hours

Creator	Rank	Followers	Posts	Engagements
@sentantiq	X	XXXXXX	X	XXX
@BiopharmIQ	X	XXXXXX	X	XX
@seedytx19	X	XXXXX	X	XX
@StockTickerZone	X	XXXXX	X	XX
@SteveDJacobs	X	XXXXX	X	X
@Stock_Marketer1	X	XXX	X	X

Sentiment: XX%

Sentiment Line Chart
Sentiment 24-Hour Time-Series Raw Data
Current Value: XX%
Daily Average: XX%
X Week: XX% -XX%
X Month: XX% -XX%
X Months: XX% -X%
X Year: XX% -XX%
1-Year High: XXX% on 2025-01-12
1-Year Low: X% on 2025-09-26

Most Supportive Themes:

FDA Approval of Epioxa: (30%) The FDA has approved Glaukos Corporation's Epioxa New Drug Application, a significant development for the company's product pipeline.
Positive Q3 Financial Results: (25%) Glaukos Corporation reported better-than-expected Q3 financial results, including revenue exceeding estimates and an increase in gross margin.
Raised FY25 Sales Guidance: (20%) The company has raised its full-year 2025 sales guidance, indicating strong future revenue expectations.

Most Critical Themes:

Market Caution Despite Positive News: (60%) Despite the FDA approval and positive financial results, the market is reacting with caution, leading to lower stock prices.
Recent Price Drops: (40%) The stock has experienced recent price drops, contributing to a cautious sentiment among investors.

Social Dominance: XXXXXXX%

Social Dominance Line Chart
Social Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: XXXXXXX%
X Week: XXXXXX% +0.001%
X Month: XXXXXX% +0.0006000000000000007%
X Months: XXXXXX% +0.003%
X Year: XXXXXX% -XXXXXX%
1-Year High: XXXXX% on 2025-06-30
1-Year Low: XXXXXX% on 2025-09-01

Market Dominance: XXXXXXX%

Market Dominance Line Chart
Market Dominance 24-Hour Time-Series Raw Data
Current Value: XXXXXXX%
Daily Average: X%
1-Year High: XXXXX% on 2025-02-19
1-Year Low: XXXXXXX% on 2025-12-11

Market Cap: $XXXXXXXXXXXXX

Market Cap Line Chart
Market Cap 24-Hour Time-Series Raw Data
Current Value: $XXXXXXXXXXXXX
Daily Average: $XXXXXXXXXXXXX
X Week: $XXXXXXXXXXXXX +$0.35%
X Month: $XXXXXXXXXXXXX +$22%
X Months: $XXXXXXXXXXXXX +$12%
X Year: $XXXXXXXXXXXXX -$20%
1-Year High: $XXXXXXXXXXXXX on 2025-01-23
1-Year Low: $XXXXXXXXXXXXX on 2025-10-24